Halozyme Therapeutics, Inc. vs. TScan Therapeutics, Inc. Common Stock
HALO
Halozyme Therapeutics, Inc.
$100.67 -1.10%
VS TCRXTScan Therapeutics, Inc. Common Stock
$0.78 +0.88%
Halozyme Therapeutics, Inc. (HALO) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| HALO | TCRX | |
|---|---|---|
| Market Cap | $11.55 billion | $52.39 million |
| Revenue (TTM) | $1.66 billion | $7.11 million |
| Net Income (TTM) | $413.60 million | $-117,712,000 |
HALO leads on 3 of 3 size & scale factors.
Valuation
| HALO | TCRX | |
|---|---|---|
| P/E Ratio | 29.35 | — |
| Price / Book | 80.48 | 0.76 |
| Price / Sales | 6.94 | 7.37 |
HALO and TCRX split the valuation factors evenly.
Profitability
| HALO | TCRX | |
|---|---|---|
| Net Margin | 24.86% | -1655.35% |
| Return on Equity | 288.13% | -170.55% |
HALO leads on 2 of 2 profitability factors.
Risk & Sentiment
| HALO | TCRX | |
|---|---|---|
| Short Interest | 9.79% | 0.01% |
TCRX leads on 1 of 1 risk & sentiment factors.
Dig deeper: HALO overview, HALO financials, TCRX overview, TCRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.